Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1999 Feb;36(2):115–118.

Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families

V Barone 1, O Massa 1, E Intravaia 1, A Bracco 1, M Di 1, V Tegazzin 1, S Cozzolino 1, V Sorrentino 1
PMCID: PMC1734304  PMID: 10051009

Abstract

Point mutations in the ryanodine receptor (RYR1) gene are associated with malignant hyperthermia, an autosomal dominant disorder triggered in susceptible people (MHS) by volatile anaesthetics and depolarising skeletal muscle relaxants. To date, 17 missense point mutations have been identified in the human RYR1 gene by screening of the cDNA obtained from muscle biopsies. Here we report single strand conformation polymorphism (SSCP) screening for nine of the most frequent RYR1 mutations using genomic DNA isolated from MHS patients. In addition, the Arg163Cys mutation was analysed by restriction enzyme digestion. We analysed 57 unrelated patients and detected seven of the known RYR1 point mutations. Furthermore, we found a new mutation, Arg2454His, segregating with the MHS phenotype in a large pedigree and a novel amino acid substitution at position 2436 in another patient, indicating a 15.8% frequency of these mutations in Italian patients. A new polymorphic site in intron 16 that causes the substitution of a G at position -7 with a C residue was identified.


Keywords: malignant hyperthermia; central core disease; ryanodine receptor; in vitro contracture test

Full Text

The Full Text of this article is available as a PDF (90.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ball S. P., Johnson K. J. The genetics of malignant hyperthermia. J Med Genet. 1993 Feb;30(2):89–93. doi: 10.1136/jmg.30.2.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Budowle B., Chakraborty R., Giusti A. M., Eisenberg A. J., Allen R. C. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet. 1991 Jan;48(1):137–144. [PMC free article] [PubMed] [Google Scholar]
  3. Eng G. D., Epstein B. S., Engel W. K., McKay D. W., McKay R. Malignant hyperthermia and central core disease in a child with congenital dislocating hips. Arch Neurol. 1978 Apr;35(4):189–197. doi: 10.1001/archneur.1978.00500280007002. [DOI] [PubMed] [Google Scholar]
  4. Fujii J., Otsu K., Zorzato F., de Leon S., Khanna V. K., Weiler J. E., O'Brien P. J., MacLennan D. H. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. 1991 Jul 26;253(5018):448–451. doi: 10.1126/science.1862346. [DOI] [PubMed] [Google Scholar]
  5. Gillard E. F., Otsu K., Fujii J., Duff C., de Leon S., Khanna V. K., Britt B. A., Worton R. G., MacLennan D. H. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics. 1992 Aug;13(4):1247–1254. doi: 10.1016/0888-7543(92)90042-q. [DOI] [PubMed] [Google Scholar]
  6. Gillard E. F., Otsu K., Fujii J., Khanna V. K., de Leon S., Derdemezi J., Britt B. A., Duff C. L., Worton R. G., MacLennan D. H. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991 Nov;11(3):751–755. doi: 10.1016/0888-7543(91)90084-r. [DOI] [PubMed] [Google Scholar]
  7. Glavac D., Dean M. Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat. 1993;2(5):404–414. doi: 10.1002/humu.1380020513. [DOI] [PubMed] [Google Scholar]
  8. Hayashi K., Yandell D. W. How sensitive is PCR-SSCP? Hum Mutat. 1993;2(5):338–346. doi: 10.1002/humu.1380020503. [DOI] [PubMed] [Google Scholar]
  9. Iles D. E., Lehmann-Horn F., Scherer S. W., Tsui L. C., Olde Weghuis D., Suijkerbuijk R. F., Heytens L., Mikala G., Schwartz A., Ellis F. R. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 1994 Jun;3(6):969–975. doi: 10.1093/hmg/3.6.969. [DOI] [PubMed] [Google Scholar]
  10. Keating K. E., Giblin L., Lynch P. J., Quane K. A., Lehane M., Heffron J. J., McCarthy T. V. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes. J Med Genet. 1997 Apr;34(4):291–296. doi: 10.1136/jmg.34.4.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Keating K. E., Quane K. A., Manning B. M., Lehane M., Hartung E., Censier K., Urwyler A., Klausnitzer M., Muller C. R., Heffron J. J. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum Mol Genet. 1994 Oct;3(10):1855–1858. doi: 10.1093/hmg/3.10.1855. [DOI] [PubMed] [Google Scholar]
  12. Lynch P. J., Krivosic-Horber R., Reyford H., Monnier N., Quane K., Adnet P., Haudecoeur G., Krivosic I., McCarthy T., Lunardi J. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Anesthesiology. 1997 Mar;86(3):620–626. doi: 10.1097/00000542-199703000-00014. [DOI] [PubMed] [Google Scholar]
  13. MacLennan D. H., Phillips M. S. Malignant hyperthermia. Science. 1992 May 8;256(5058):789–794. doi: 10.1126/science.1589759. [DOI] [PubMed] [Google Scholar]
  14. Manning B. M., Quane K. A., Lynch P. J., Urwyler A., Tegazzin V., Krivosic-Horber R., Censier K., Comi G., Adnet P., Wolz W. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia. Hum Mutat. 1998;11(1):45–50. doi: 10.1002/(SICI)1098-1004(1998)11:1<45::AID-HUMU7>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  15. Manning B. M., Quane K. A., Ording H., Urwyler A., Tegazzin V., Lehane M., O'Halloran J., Hartung E., Giblin L. M., Lynch P. J. Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet. 1998 Mar;62(3):599–609. doi: 10.1086/301748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Monnier N., Procaccio V., Stieglitz P., Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997 Jun;60(6):1316–1325. doi: 10.1086/515454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Phillips M. S., Fujii J., Khanna V. K., DeLeon S., Yokobata K., de Jong P. J., MacLennan D. H. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics. 1996 May 15;34(1):24–41. doi: 10.1006/geno.1996.0238. [DOI] [PubMed] [Google Scholar]
  18. Phillips M. S., Khanna V. K., De Leon S., Frodis W., Britt B. A., MacLennan D. H. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. Hum Mol Genet. 1994 Dec;3(12):2181–2186. doi: 10.1093/hmg/3.12.2181. [DOI] [PubMed] [Google Scholar]
  19. Quane K. A., Healy J. M., Keating K. E., Manning B. M., Couch F. J., Palmucci L. M., Doriguzzi C., Fagerlund T. H., Berg K., Ording H. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993 Sep;5(1):51–55. doi: 10.1038/ng0993-51. [DOI] [PubMed] [Google Scholar]
  20. Quane K. A., Keating K. E., Healy J. M., Manning B. M., Krivosic-Horber R., Krivosic I., Monnier N., Lunardi J., McCarthy T. V. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics. 1994 Sep 1;23(1):236–239. doi: 10.1006/geno.1994.1483. [DOI] [PubMed] [Google Scholar]
  21. Quane K. A., Keating K. E., Manning B. M., Healy J. M., Monsieurs K., Heffron J. J., Lehane M., Heytens L., Krivosic-Horber R., Adnet P. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet. 1994 Mar;3(3):471–476. doi: 10.1093/hmg/3.3.471. [DOI] [PubMed] [Google Scholar]
  22. Quane K. A., Ording H., Keating K. E., Manning B. M., Heine R., Bendixen D., Berg K., Krivosic-Horber R., Lehmann-Horn F., Fagerlund T. Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia. Br J Anaesth. 1997 Sep;79(3):332–337. doi: 10.1093/bja/79.3.332. [DOI] [PubMed] [Google Scholar]
  23. Sudbrak R., Golla A., Hogan K., Powers P., Gregg R., Du Chesne I., Lehmann-Horn F., Deufel T. Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum Mol Genet. 1993 Jul;2(7):857–862. doi: 10.1093/hmg/2.7.857. [DOI] [PubMed] [Google Scholar]
  24. Sudbrak R., Procaccio V., Klausnitzer M., Curran J. L., Monsieurs K., van Broeckhoven C., Ellis R., Heyetens L., Hartung E. J., Kozak-Ribbens G. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet. 1995 Mar;56(3):684–691. [PMC free article] [PubMed] [Google Scholar]
  25. Tong J., Oyamada H., Demaurex N., Grinstein S., McCarthy T. V., MacLennan D. H. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem. 1997 Oct 17;272(42):26332–26339. doi: 10.1074/jbc.272.42.26332. [DOI] [PubMed] [Google Scholar]
  26. Zhang Y., Chen H. S., Khanna V. K., De Leon S., Phillips M. S., Schappert K., Britt B. A., Browell A. K., MacLennan D. H. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet. 1993 Sep;5(1):46–50. doi: 10.1038/ng0993-46. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES